Management of drug and alcohol withdrawal

New England Journal of Medicine

Volumn 348, Issue 18, 2003, Pages 1786-1795

  Kosten, Thomas R ^a,b   O'Connor, Patrick G ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Psychology Service   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ALPRAZOLAM; ANALGESIC AGENT; ANESTHETIC AGENT; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; ATENOLOL; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUPRENORPHINE; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CLONIDINE; DIAZEPAM; DOPAMINE RECEPTOR STIMULATING AGENT; GABAPENTIN; HALAZEPAM; LOFEXIDINE; LORAZEPAM; METHADONE; NALOXONE; NALTREXONE; OPIATE; OXAZEPAM; PHENOBARBITAL; PROPRANOLOL; SEDATIVE AGENT; UNINDEXED DRUG; VALPROIC ACID;

ABSTINENCE; ADVERSE DRUG REACTION; AGITATION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ANAMNESIS; ANOREXIA; ANXIETY; CLINICAL FEATURE; CLINICAL TRIAL; DELIRIUM TREMENS; DEPRESSION; DIAGNOSTIC ACCURACY; DIARRHEA; DRUG DEPENDENCE; DRUG DETOXIFICATION; DRUG SAFETY; DYSPHORIA; GOOSEFLESH; HUMAN; HYPERTENSION; INSOMNIA; IRRITABILITY; LACRIMATION; MYDRIASIS; NAUSEA; OUTPATIENT; PATIENT CARE; PRIORITY JOURNAL; PSYCHOSIS; QUESTIONNAIRE; REVIEW; RHINORRHEA; SCREENING; SNEEZING; SUICIDAL BEHAVIOR; SYMPTOM; TACHYCARDIA; VERTIGO; VOMITING; WITHDRAWAL SYNDROME; YAWNING;

ADRENERGIC ALPHA-AGONISTS; ALCOHOLISM; AMBULATORY CARE; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; BENZODIAZEPINES; DRUG THERAPY, COMBINATION; HUMANS; NARCOTIC ANTAGONISTS; NARCOTICS; PHYSICIAN'S ROLE; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 0037407734     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra020617     Document Type: Review

References (67)

1. National Household Survey on Drug Abuse (NHSDA). Washington, D.C.: Substance Abuse and Mental Health Services Administration (SAMHSA), 1999.
2. Manwell LB, Fleming MF, Johnson K, Barry KL. Tobacco, alcohol, and drug use in a primary care sample: 90-day prevalence and associated factors. J Addict Dis 1998;17:67-81.
3. O'Connor PG, Fiellin DA. Pharmacologic treatment of heroin-dependent patients. Ann Intern Med 2000;133:40-54.
4. O'Connor PG, Samet JH, Stein MD. Management of hospitalized intravenous drug users: role of the internist. Am J Med 1994;96:551-8.
5. Carroll KM. Relapse prevention as a psychosocial treatment approach: a review of controlled clinical trials. Exp Clin Psychopharm 1996;4:46-54.
6. Petry NM. A comprehensive guide to the application of contingency management procedures in clinical settings. Drug Alcohol Depend 2000;58:9-25.
7. O'Connor PG, Schottenfeld RS. Patients with alcohol problems. N Engl J Med 1998;338:592-602.
8. Mayo-Smith MF. Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline: American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA 1997;278:144-51.
9. Davis KM, Wu JY. Role of glutaminergic and GABAergic systems in alcoholism. J Biomed Sci 2000;8:7-19.
10. Mayo-Smith MF, Bernard D. Late-onset seizures in alcohol withdrawal. Alcohol Clin Exp Res 1995;19:656-9.
11. Nutt D. Alcohol and the brain: pharmacological insights for psychiatrists. Br J Psychiatry 1999;175:114-9.
12. Lejoyeux M, Solomon J, Ades J. Benzodiazepine treatment for alcohol-dependent patients. Alcohol Alcohol 1998;33:563-75.
13. Tsai G, Coyle JT. The role of glutamatergic neurotransmission in the pathophysiology of alcoholism. Annu Rev Med 1998;49:173-84.
14. Saitz R, Mayo-Smith MF, Roberts MS, Redmond HA, Bernard D, Calkins DR. Individualized treatment for alcohol withdrawal: a randomized double-blind controlled trial. JAMA 1994;272:519-23.
15. Reoux JP, Miller K. Routine hospital alcohol detoxification practice compared to symptom triggered management with an Objective Withdrawal Scale (CIWA-Ar). Am J Addict 2000;9:135-44.
16. Satel SL, Kosten TR, Schuckit MA, Fischman MW. Should protracted withdrawal from drugs be included in DSM-IV? Am J Psychiatry 1993;150:695-704.
17. Adinoff B. Double-blind study of alprazolam, diazepam, clonidine, and placebo in the alcohol withdrawal syndrome: preliminary findings. Alcohol Clin Exp Res 1994;18:873-8.
18. Griffiths RR, Wolf B. Relative abuse liability of different benzodiazepines in drug abusers. J Clin Psychopharmacol 1990;10:237-43.
19. Hobbs WR, Rall TW, Verdoorn TA. Hypnotics and sedatives, alcohol. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill, 1996:361-98.
20. Holbrook AM, Crowther R, Lotter A, Cheng C, King D. Meta-analysis of benzodiazepine use in the treatment of acute alcohol withdrawal. CMAJ 1999;160:649-55.
21. Smith DE, Wesson DR. Benzodiazepines and other sedative hypnotics. In: Galanter M, Kleber HD, eds. The American Psychiatric Press textbook of substance abuse treatment. 2nd ed. Washington, D.C.: American Psychiatric Press, 1999:239-50.
22. Palestine ML, Alatorre E. Control ofacute alcoholic withdrawal symptoms: a comparative study of haloperidol and chlordiazepoxide. Curr Ther Res Clin Exp 1976;20:289-99.
23. Horwitz RI, Gottlieb LD, Kraus ML. The efficacy of atenolol in the outpatient management of the alcohol withdrawal syndrome: results of a randomized clinical trial. Arch Intern Med 1989;149:1089-93.
24. Worner TM. Propranolol versus diazepam in the management of the alcohol withdrawal syndrome: double-blind controlled trial. Am J Drug Alcohol Abuse 1994;20:115-24.
25. Zilm DH, Jacob MS, MacLeod SM, Sellers EM, Ti TY. Propranolol and chlordiazepoxide effects on cardiac arrhythmias during alcohol withdrawal. Alcohol Clin Exp Res 1980;4:400-5.
26. Robinson BJ, Robinson GM, Maling TJ, Johnson RH. Is clonidine useful in the treatment of alcohol withdrawal? Alcohol Clin Exp Res 1989;13:95-8.
27. Malcolm R, Myrick H, Roberts J, Wang W, Anton RF, Ballenger JC. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. J Gen Intern Med 2002;17:349-55.
28. Bjorkqvist SE, Isohanni M, Makela P, Malinen L. Ambulant treatment of alcohol withdrawal symptoms with carbamazepine: a formal multicentre double-blind comparison with placebo. Acta Psychiatr Scand 1976;53:333-42.
29. Malcolm R, Ballenger JC, Sturgis ET, Anton R. Double-blind controlled trial comparing carbamazepine to oxazepam treatment of alcohol withdrawal. Am J Psychiatry 1989;146:617-21.
30. Stuppaeck CH, Pycha R, Miller C, Whitworth AB, Oberbauer H, Fleischhacker WW. Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: a double-blind study. Alcohol Alcohol 1992;27:153-8.
31. Chu NS. Carbamazepine: prevention of alcohol withdrawal seizures. Neurology 1979;29:1397-401.
32. Malcolm R, Myrick H, Brady KT, Ballenger JC. Update on anticonvulsants for the treatment of alcohol withdrawal. Am J Addict 2001;10:Suppl:16-23.
33. Pages KP, Ries RK. Use of anticonvulsants in benzodiazepine withdrawal. Am J Addict 1998;7:198-204.
34. Reoux JP, Saxon AJ, Malte CA, Baer JS, Sloan KL. Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. Alcohol Clin Exp Res 2001;25:1324-9.
35. Kleber HD. Opiods: detoxification. In: Galanter M, Kleber HD, eds. The American Psychiatric Press textbook of substance abuse treatment. 2nd ed. Washington, D.C.: American Psychiatric Press, 1999:251-69.
36. Jasinski DR, Pevnick JS, Griffith JD. Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978;35:501-16.
37. O'Connor PG. Treating opioid dependence - new data and new opportunities. N Engl J Med 2000;343:1332-4.
38. Fiellin DA, O'Connor PG. Office-based treatment of opioid-dependent patients. N Engl J Med 2002;347:817-23.
39. Kosten TR, Krystal JH, Charney DS, Price LH, Morgan CH, Kleber HD. Rapid detoxification from opioid dependence. Am J Psychiatry 1989;147:1349.
40. Cheskin LJ, Fudala PJ, Johnson RE. A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug Alcohol Depend 1994;36:115-21.
41. Senay EC, Dorus W, Goldberg F, Thornton W. Withdrawal from methadone maintenance: rate of withdrawal and expectation. Arch Gen Psychiatry 1977;34:361-7.
42. Kleber HD, Riordan CE, Rounsaville B, et al. Clonidine in outpatient detoxification from methadone maintenance. Arch Gen Psychiatry 1985;42:391-4.
43. Sees KL, Delucchi KL, Masson C, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA 2000;283:1303-10.
44. Kosten TR. Neurobiology of abused drugs: opioids and stimulants. J Nerv Ment Dis 1990;178:217-27.
45. Jasinski DR, Johnson RE, Kocher TR, Clonidine in morphine withdrawal: differential effects on signs and symptoms. Arch Gen Psychiatry 1985;42:1063-6.
46. O'Connor PG, Waugh ME, Carroll KM, Kounsaville BJ, Diagkogiannis IA, Schottenfeld RS. Primary care-based ambulatory opiold detoxification: the results of a clinical trial. J Gen Intern Med 1995;10:255-60.
47. Strang J, Bearn J, Gossop M. Lofexidine for opiate detoxification: review of recent randomised and open controlled trials. Am J Addict 1999;8:337-48.
48. Vining E, Kosten TR, Kleber HD. Clinical utility of rapid clonidine-naltrexone detoxification for opioid abusers. Br J Addict 1988;83:567-75.
49. O'Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ. Three methods of opioid detoxification in a primary care setting: a randomized trial. Ann Intern Med 1997;127:526-30.
50. Presslich O, Loimer N, Lenz K, Schmid R. Opiate detoxification under general anesthesia by large doses of naloxone. J Toxicol Clin Toxicol 1989;27:263-70.
51. Loimer N, Lenz K, Schmid R, Presslich O. Technique for greatly shortening the transition from methadone to naltrexone maintenance of patients addicted to opiates. Am J Psychiatry 1991;148:933-5.
52. O'Connor PG, Kosten TR. Rapid and ultra-rapid opioid detoxification techniques. JAMA 1998;279:229-34.
53. Rabinowitz J, Cohen H, Tarrasch R, Kotler M. Compliance to naltrexone treatment after ultra-rapid opiate detoxification: an open label naturalistic study. Drug Alcohol Depend 1997;47:77-86.
54. Cucchia AT, Monnat M, Spagnoli J, Ferrero F, Bertschy G. Ultra-rapid opiate detoxification using deep sedation with oral midazolam: short and long-term results. Drug Alcohol Depend 1998;52:243-50.
55. Scherbaum N, Klein S, Kaube H, Kienbaum P, Peters J, Gastpar M. Alternative strategies of opiate detoxification: evaluation of the so-called ultra-rapid detoxification. Pharmacopsychiatry 1998;31:205-9.
56. Pfab R, Hird C, Zilker T. Opiate detoxification under anesthesia: no apparent benefit but suppression of thyroid hormones and risk of pulmonary and renal failure. J Clin Toxicol 1999;37:43-50.
57. Kosten TR. Pathophysiology and treatment of cocaine dependence. In: Davis K, Charney D, Coyle JT, Nemeroff C, eds. Neuropsychopharmacology: the fifth generation of progress. Baltimore: Lippincott Williams & Wilkins, 2002:1461-73.
58. Markou A, Kosten TR, Koob GF. Neurobiological similarities in depression and drug dependence: a self-medication hypothesis. Neuropsychopharmacology 1998;18:135-74.
59. Mendelson JH, Mello NK. Management of cocaine abuse and dependence. N Engl J Med 1996;334:965-72.
60. Kosten TR, George TP, Kosten TA. The potential of dopamine agonists in drug addiction. Expert Opin Investig Drugs 2002;11:491-9.
61. Moscovitz H, Brookoff D, Nelson L. A randomized trial of bromocriptine for cocaine users presenting to the emergency department. J Gen Intern Med 1993;8:1-4.
62. Malcolm R, Kajdasz DK, Herron J, Anton RF, Brady KT. A double-blind, placebo-controlled outpatient trial of pergolide for cocaine dependence. Drug Alcohol Depend 2000;60:161-8.
63. Grabowski J, Roache JD, Schmitz JM, Rhoades H, Creson D, Korszun A. Replacement medication for cocaine dependence: methylphenidate. J Clin Psychopharmacol 1997;17:485-8.
64. Alterman AI, Droba M, Antelo RE, et al. Amantadine may facilitate detoxification of cocaine addicts. Drug Alcohol Depend 1992;31:19-29.
65. Kampman KM, Volpicelli JR, Mulvaney F, et al. Effectiveness of propranolol for cocaine dependence treatment may depend on cocaine withdrawal symptom severity. Drug Alcohol Depend 2001;63:69-78.
66. Cornelius JR, Salloum IM, Ehler JG, et al. Fluoxetine in depressed alcoholics: a double-blind, placebo-controlled trial. Arch Gen Psychiatry 1997;54:700-5.
67. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999;340:685-91.